Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2007

View Archived Issues

Marshall Edwards recruiting patients in phase III trial of phenoxodiol

NeuralSTEM and University of Michigan to collaborate on stem cell R&D

GlaxoSmithKline receives European authorization for Arixtra in the treatment of ACS

Positive results for Accera's phase II study of Ketasyn for memory in older adults

New analgesic agents described in recent patent literature

Novel agents for neurological disorders reported in recent Proximagen and Janssen patents

Recent Merck & Co. patent imparts new treatment option for atherosclerosis

Modulation of mGlu5 receptor activity may provide benefit in incontinence and overactive bladder

Merck Serono applies to EMEA for extension of Erbitux indication in mCRC

Amgen describes new 11beta-HSD1 inhibitors with potential use in treating type 2 diabetes

Abbott and AstraZeneca to advance ABT-335 and Crestor combination

FDA extends Astellas Pharma US's Mycamine for injection sNDA three months

Wistar Institute's novel HIV vaccine receives funding for clinical trials

Improved antitumor activity and safety profile of nitric oxide derivative of pegylated epirubicin

Neuroprotective effects of coumaric acid derivative identified

Smallpox vaccine ACAM-2000 approved by FDA

Mylan begins offers for senior notes towards acquisition of Merck's generic pharmaceutical business

Meridian Bioscience begins parvovirus B19 vaccine phase I/II trials

ThromboGenics completes technology transfer to Bharat Biotech for THR-100

Positive interim results from Avexa's phase IIb trial of apricitabine for HIV

E-5555 inhibits thrombin-induced platelet aggregation in healthy volunteers

Extended release niacin/laropiprant demonstrates efficacy in dyslipidemia

Studies show improved lipids, no blood pressure increase with MK-0859

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...